## AAPG: Ascentage Pharma Group Internat - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -7.7% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($27.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%**
- Source: GlobeNewswire | 20251209T000859 | Bullish | Relevance: 98%
-  Ascentage Pharma presented the first dataset from the global registrational Phase III POLARIS-1 study of Olverembatinib (HQP1351) in combination with low-intensity chemotherapy for newly diagnosed Ph+ ALL. The data showed a best minimal residual disease (MRD) negativity rate of 66.0% and an MRD-negative complete response (CR) rate of 64.2% by the end of 3 induction cycles, alongside a favorable safety profile. The study highlights Olverembatinib's potential to reshape the therapeutic landscape for Ph+ ALL and was recently cleared by the U.S. FDA and European Medicines Agency (EMA).

**2. ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP**
- Source: www.yourcentralvalley.com | 20251209T000859 | Bullish | Relevance: 97%
- Ascentage Pharma presented four-year follow-up data from its Phase II study of Olverembatinib at the ASH 2025 Annual Meeting. The data reconfirm Olverembatinib's long-term efficacy and safety in patients with TKI-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP), including those without the T315I mutation. The drug showed a significantly longer event-free survival compared to best available therapy and a favorable safety profile with a 7% vascular occlusion rate.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Oppenheimer | $45 | $0 | 0% |
| 2025-11-24 | Truist Securiti | $51 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Oppenheimer | init | Outperform |
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 0.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- UBS Group AG: 0.0% (+149.4%)
- XY Capital Ltd: 0.0% (+224.1%)
- Point72 (DIFC) Ltd: 0.0% (-14.2%)
- Tema Etfs LLC       : 0.0% (-33.0%)
- ABC Arbitrage SA: 0.0% (+100.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.5% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 6.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 244% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.8B |
| Beta | 1.11 |
| 52W Range | $16.50 - $48.45 |
| Short Interest | 0.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from -0.2% to -7.7% (-7.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.7pp (needs >4.0% for momentum thesis). AM_20 at -5.7% indicates price below own 20MA trend. Underperforming sector by 5.4pp, stock-specific weakness. Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 41.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.71% (CS: 4) | Weak |
| RSI_14 | 40.6 | Neutral |
| MACD Histogram | -0.08 | Bearish |
| vs SMA20 | 0.943x | Below |
| vs SMA50 | 0.884x | Below |
| vs SMA200 | 0.939x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $29.99
- **Stop Loss:** $27.39 (8.7% risk)
- **Target:** $32.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 530
- **Position Value:** $15,894.70
- **Portfolio %:** 15.89%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-03-26 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*